N/A
N=72
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II
Cancer-related Problem/Condition · Cognitive Impairment
Bottom Line
View on ClinicalTrials.gov: NCT04669301 ↗Enrolled (actual)
72
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Mean of the Functional Assessment of Cancer Therapy-Cognition (FACT-COG) — 155.8; 152.7 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- MAAT-G (Behavioral); Supportive therapy (time and attention control) (Behavioral)
- Age
- Older Adult · 65+ yrs
- Sex
- All
- Sponsor
- University of Rochester
- Primary completion
- Apr 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean of the Functional Assessment of Cancer Therapy-Cognition (FACT-COG) |
155.8; 152.7 | — |
| SECONDARY Least Squares Mean for Delay Match to Sample Total Correct at the 12-second Delay (DMSTC-12) From the Cambridge Neuropsychological Test Automated Battery (CANTAB) |
4.04; 4.10 | — |
| SECONDARY Mean of the Controlled Oral Word Association (COWA) Tool |
12.4; 11.4 | — |
| SECONDARY Mean of the Hopkins Verbal Learning Test-Revised (HVLT-R) |
8; 7.7 | — |
| SECONDARY Mean of the Geriatric Depression Screen (GDS) |
2.3; 3.3 | — |
| SECONDARY Mean of the Generalized Anxiety and Depression 7-item Scale (GAD-7) |
3.4; 4 | — |
| SECONDARY Mean of the Instrumental Activities of Daily Living (IADL) |
12.8; 12.9 | — |
| SECONDARY Experience Interview - Proportion of Patients Who Expressed Perceived Benefit From Workshops. |
16; 28 | — |
Summary
Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training (MAAT) is a promising treatment for CRCD that improves perceived cognition in younger cancer survivors, but needs to be adapted for older adults to address their unique needs. The proposed study will adapt MAAT for older adults using feedback from key stakeholders (older adults with cancer and their caregivers), and subsequently test the ability of MAAT to improve or maintain cognition for older adults with breast cancer receiving adjuvant chemotherapy.
Eligibility Criteria
Inclusion Criteria
- Have a diagnosis of invasive breast cancer
- Planned to receive systemic therapy for breast cancer or actively receiving systemic therapy for breast cancer with two additional cycles remaining.
- Be age 65 or older
- Able to provide informed consent
- Able to read and understand English (or possess a designated health care proxy that can do the same that was designated prior to the patient losing decision-making capabilities)
Exclusion Criteria
- Have surgery planned within 3 months of consent
- Patients who do not have decision-making capacity (decisionally or cognitively impaired) AND do NOT have a previously designated health care proxy (established prior to their cognitive impairment) available to sign consent
- Patients with breast cancer receiving endocrine therapy as their only systemic therapy will not be eligible.
Data sourced from ClinicalTrials.gov (NCT04669301). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.